Table 1: Basal data, comorbidity, initial clinical and microbiological data in patients with Ceftaroline and another antibiotic.
|
Ceftaroline (N = 34) (28.1%) |
Another Antibiotic (N = 87) (71.9%) |
p |
Sex male |
20 (58.8%) |
65 (74.7%) |
0.09 |
Age (years) |
55.1 ± 15.5 |
63.1 ± 15.2 |
0.01 |
Institutionalized |
0 |
4 (4.6%) |
0.204 |
Comorbidity |
|
|
|
Smoke |
12 (35.3%) |
21 (24.1%) |
0.216 |
Diabetes mellitus |
8 (23.5%) |
18 (20.7%) |
0.732 |
Alcohol abuse |
0 |
4 (4.6%) |
0.204 |
Neoplasm |
3 (8.8%) |
2 (2.3%) |
0.105 |
COPD |
7 (20.6%) |
21 (24.1%) |
0.677 |
Asthma |
2 (5.9%) |
0 |
0.023 |
Chronic hepatopathy |
4 (11.8%) |
7 (8%) |
0.522 |
Corticoids |
2 (5.9%) |
11 (12.6%) |
0.280 |
Immunosuppressor therapy |
2 (5.9%) |
6 (6.9%) |
0.840 |
Initial data in ICU |
|
|
|
Type of sepsis |
|
|
|
Sepsis |
8 (23.5%) |
43 (49.4%) |
|
Septic shock |
26 (76.5%) |
44 (50.6%) |
0.01 |
Mechanical Ventilation |
22 (64.7%) |
35 (40.2%) |
0.01 |
Vasoactive drugs |
28 (82.4%) |
44 (50.6%) |
0.001 |
Procalcitonin (ng/ml) |
23.6 ± 28.5 |
11.8 ± 23.6 |
0.025 |
Procalcitonin at third day (ng/ml) |
6.9 ± 7.2 |
6.4 ± 11.1 |
0.803 |
ICU associated treatment |
|
|
|
Macrolide |
18 (90%) |
22 (45.8%) |
0.001 |
Quinolone |
13 (86.7%) |
57 (78.1%) |
0.453 |
Corticoids |
9 (26.5%) |
27 (31.4%) |
0.596 |
Microbiological data |
|
|
|
Positive blood culture |
14 (41.2%) |
8 (9.4%) |
< 0.001 |
Positive Bronquial secretion culture positivo |
7 (20.6%) |
12 (13.8%) |
0.356 |
Positive urine Antigens |
16 (47.1%) |
18 (20.7%) |
0.004 |
Results |
|
|
|
Pneumococcus |
17 (50%) |
18 (20.7%) |
|
Others |
4 (11.8%) |
22 (25.3%) |
|
Negative |
13 (38.2%) |
47 (54%) |
0.005 |
Another antibiotic group includes treatment with ceftriaxone, piperacillin tazobactam, cefepime or cloxacillin. Quantitative data are expressed like median ± standard deviation and categoric data like percentage. COPD: Chronic obstructive pulmonary disease; ICU: Intensive care unit [2].